Strongbridge Biopharma (NASDAQ:SBBP) Stock Price Up 5.2%

Strongbridge Biopharma plc (NASDAQ:SBBP) rose 5.2% on Thursday . The stock traded as high as $3.31 and last traded at $3.24. Approximately 262,817 shares changed hands during trading, an increase of 41% from the average daily volume of 186,347 shares. The stock had previously closed at $3.08.

SBBP has been the topic of several research analyst reports. Oppenheimer reiterated a “buy” rating on shares of Strongbridge Biopharma in a research report on Tuesday, March 19th. Zacks Investment Research upgraded shares of Strongbridge Biopharma from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a research report on Tuesday, March 19th. TheStreet cut shares of Strongbridge Biopharma from a “c-” rating to a “d+” rating in a research report on Wednesday, May 15th. Finally, ValuEngine upgraded shares of Strongbridge Biopharma from a “sell” rating to a “hold” rating in a research report on Monday, March 25th. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $13.14.

The firm’s 50 day simple moving average is $3.07. The company has a market capitalization of $175.52 million, a P/E ratio of 10.10 and a beta of 0.78.

Strongbridge Biopharma (NASDAQ:SBBP) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.09. The company had revenue of $4.34 million during the quarter, compared to analyst estimates of $4.69 million. Strongbridge Biopharma had a net margin of 227.79% and a return on equity of 79.31%. On average, equities analysts predict that Strongbridge Biopharma plc will post -1.36 EPS for the current year.

Large investors have recently modified their holdings of the business. Stonebridge Capital Management Inc. acquired a new stake in shares of Strongbridge Biopharma during the 1st quarter valued at $55,000. Stifel Financial Corp acquired a new stake in shares of Strongbridge Biopharma during the 4th quarter valued at $73,000. Oppenheimer & Co. Inc. boosted its stake in shares of Strongbridge Biopharma by 90.8% during the 1st quarter. Oppenheimer & Co. Inc. now owns 45,448 shares of the biotechnology company’s stock valued at $226,000 after buying an additional 21,626 shares during the period. Private Advisors LLC acquired a new stake in shares of Strongbridge Biopharma during the 1st quarter valued at $263,000. Finally, Tibra Equities Europe Ltd acquired a new stake in shares of Strongbridge Biopharma during the 1st quarter valued at $324,000. 50.12% of the stock is owned by institutional investors.

Strongbridge Biopharma Company Profile (NASDAQ:SBBP)

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency.

Further Reading: Trading Strategy Examples and Plans

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.